TP53 and prostate carcinoma: Through network pharmacology analysis, malayoside may inhibit prostate cancer by regulating PRAD cell proliferation and death by nuclear receptors (NR), MAPK, PI3K/AKT, TP53, Bcl-2, matrix metalloproteinases (MMPs), and their signaling pathways, especially with NRs and MAPKs.